Exsight Ventures

About The Fund

ExSight Ventures is a venture capital firm that specializes in early-stage impact investments in innovative ophthalmic diagnostic and treatment solutions. They seek to invest in biotechnology, medical devices, pharmaceuticals, and software solutions in the field of ophthalmology. ExSight Ventures aims to address the lack of early-stage funding available to life science companies. The firm is returns-oriented, mission-focused, and heavily relies on the deep domain expertise and networks of its team, which includes two accomplished retinal surgeons. This expertise is leveraged in the investment selection process to assist portfolio companies effectively. The firm's investment thesis is built upon capital efficient techniques and focuses on early-stage companies developing breakthrough technologies to aid, diagnose, and treat large populations afflicted with vision diseases. They believe that their specialization in ophthalmology provides an advantage over generalist investors. They can efficiently analyze early-stage risks due to close contacts with major innovators, scientists, leading academicians, and strategic partners, which also maximizes potential collaborations and partnerships for portfolio companies. ExSight Ventures invests predominantly in pre-seed to Series B rounds where their investment can generate substantial value. With a firm focus on capital efficiency, they invest mostly in technology development rather than staffing and sales, maximizing the potential for exponential value creation from their investments. Furthermore, the firm argues that diversification should be achieved by diversifying across managers with deep domain expertise, rather than across holdings within a manager. ExSight Ventures operates under the belief that the eye's unique anatomical features make it an ideal proving ground for innovative technologies, and external factors such as an aging population, a global increase in diabetes, and an expanding global middle class drive the need for innovation in eye care. Their approach differentiates them from the mega funds in healthcare venture capital and positions them as an ideal partner for promising early-stage companies.